Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

被引：6
|
作者：
Antonarakis, Emmanuel S.
Goh, Jeffrey C.
Gross-Goupil, Marine
Vaishampayan, Ulka N.
Piulats, Josep M.
De Wit, Ronald
Alanko, Tuomo
Fukasawa, Satoshi
Tabata, Kenichi
Feyerabend, Susan
Berger, Raanan
Wu, Haiyan
Kim, Jeri
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[3] Univ Hosp Bordeaux, Bordeaux, France
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Hosp Duran & Reynals, Inst Catalan Oncol, Barcelona, Spain
[6] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[7] Docrates Canc Ctr, Helsinki, Finland
[8] Chiba Canc Ctr, Chiba, Japan
[9] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[10] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[11] MSD China, Beijing, Peoples R China
[12] Merck & Co Inc, Kenilworth, NJ USA
[13] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
216
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [22] Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
    Antonarakis, E. S.
    Piulats, J. M.
    Gross-Goupil, M.
    Goh, J. C.
    Vaishampayan, U. N.
    De Wit, R.
    Alanko, T. V.
    Fukasawa, S.
    Tabata, K.
    Feyerabend, S.
    Berger, R.
    Ojamaa, K.
    Hoimes, C. J.
    Sezer, A.
    Omlin, A. G.
    Yachnin, J.
    Niu, C.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S651 - S652
  • [23] Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
    Fong, Peter C. C.
    Kwiatkowski, Mariusz
    Mosca, Alessandra
    Valderrama, Begona Perez
    Huang, Yi-Hsiu
    Zedan, Ahmed H.
    Kuc, Kamil
    Wiechno, Pawel
    Laguerre, Brigitte
    Gonzalez-Billalabeitia, Enrique
    Osipov, Mikhail
    Dede, Didem Sener
    Goh, Jeffrey
    Daugaard, Gedske
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    Arija, Jose Angel Arranz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 149 - 149
  • [24] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [25] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Fer, Tilman Todenho Spacing Diaeresis
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Saretsky, Todd L.
    Ghate, Sameer R.
    Li, Xin Tong
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
    Paredero Perez, I.
    Arnal, M.
    Lorente, D.
    Girones Sarrio, R.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Llacer Perez, C.
    Castro Marcos, E.
    Olmos, D.
    Sanchez Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S526 - S526
  • [28] Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
    Petrylak, D. P.
    Shore, N. D.
    Bennamoun, M.
    Ratta, R.
    Piulats, J. M.
    Li, B.
    Schloss, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1332 - S1333
  • [29] Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
    Thoman, Maxton E.
    Salari, Keyan
    EUROPEAN UROLOGY, 2022, 82 (01) : 31 - 33
  • [30] Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
    Brasso, Klaus
    Thomsen, Frederik B.
    Schrader, Andres J.
    Schmid, Sebastian C.
    Lorente, David
    Retz, Margitta
    Merseburger, Axel S.
    von Klot, Christoph A.
    Boegemann, Martin
    de Bono, Johann
    EUROPEAN UROLOGY, 2015, 68 (02) : 317 - 324
12345